{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:02:24Z","timestamp":1794646944296,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fully funded by the Cell Therapy Development Program at Celloram Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74891-3","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:02:10Z","timestamp":1785142930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7949-9160","authenticated-orcid":false,"given":"Jin Muk","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-6775","authenticated-orcid":false,"given":"Eun Hyang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Kyu","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5696-5386","authenticated-orcid":false,"given":"Seunghee","family":"Youm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tej","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liraz","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0437-6323","authenticated-orcid":false,"given":"John","family":"Letterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghwan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"74891_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","volume":"137","author":"RM Steinman","year":"1973","unstructured":"Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution.  J. Exp. Med. 137, 1142\u20131162 (1973).","journal-title":"J. Exp. Med."},{"key":"74891_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","volume":"449","author":"RM Steinman","year":"2007","unstructured":"Steinman, R. M. & Banchereau, J. Taking dendritic cells into medicine. Nature 449, 419\u2013426 (2007).","journal-title":"Nature"},{"key":"74891_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.7774\/cevr.2014.3.2.113","volume":"3","author":"MS Ahmed","year":"2014","unstructured":"Ahmed, M. S. & Bae, Y. S. Dendritic cell-based therapeutic cancer vaccines: past, present and future. Clin. Exp. Vaccin. Res 3, 113\u2013116 (2014).","journal-title":"Clin. Exp. Vaccin. Res"},{"key":"74891_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117858","volume":"184","author":"M Sheykhhasan","year":"2025","unstructured":"Sheykhhasan, M. et al. Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy. Biomed. Pharmacother. 184, 117858 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"74891_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.trsl.2015.07.008","volume":"168","author":"J Constantino","year":"2016","unstructured":"Constantino, J., Gomes, C., Falcao, A., Cruz, M. T. & Neves, B. M. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl. Res 168, 74\u201395 (2016).","journal-title":"Transl. Res"},{"key":"74891_CR6","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F. & Berneman, Z. N. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 15, e257\u2013e267 (2014).","journal-title":"Lancet Oncol."},{"key":"74891_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12319-x","volume":"10","author":"E Menares","year":"2019","unstructured":"Menares, E. et al. Tissue-resident memory CD8(+) T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells. Nat. Commun. 10, 4401 (2019).","journal-title":"Nat. Commun."},{"key":"74891_CR8","doi-asserted-by":"publisher","first-page":"e16523","DOI":"10.15252\/emmm.202216523","volume":"14","author":"A Martinez-Usatorre","year":"2022","unstructured":"Martinez-Usatorre, A. & De Palma, M. Dendritic cell cross-dressing and tumor immunity. EMBO Mol. Med. 14, e16523 (2022).","journal-title":"EMBO Mol. Med."},{"key":"74891_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri724","volume":"2","author":"CL Vanderlugt","year":"2002","unstructured":"Vanderlugt, C. L. & Miller, S. D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2, 85\u201395 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"74891_CR10","doi-asserted-by":"crossref","unstructured":"Lo, J. A. et al. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci. Transl. Med. 13, eabd8636(2021).","DOI":"10.1126\/scitranslmed.abd8636"},{"key":"74891_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"74891_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nature04651","volume":"440","author":"F Castellino","year":"2006","unstructured":"Castellino, F. et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440, 890\u2013895 (2006).","journal-title":"Nature"},{"key":"74891_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/ni1104-1097","volume":"5","author":"PG Ashton-Rickardt","year":"2004","unstructured":"Ashton-Rickardt, P. G. A license to remember. Nat. Immunol. 5, 1097\u20131098 (2004).","journal-title":"Nat. Immunol."},{"key":"74891_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1084\/jem.187.5.693","volume":"187","author":"F Ossendorp","year":"1998","unstructured":"Ossendorp, F., Mengede, E., Camps, M., Filius, R. & Melief, C. J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.  J. Exp. Med. 187, 693\u2013702 (1998).","journal-title":"J. Exp. Med."},{"key":"74891_CR15","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"74891_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692\u2013696 (2015).","journal-title":"Nature"},{"key":"74891_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/368215a0","volume":"368","author":"LJ Stern","year":"1994","unstructured":"Stern, L. J. et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215\u2013221 (1994).","journal-title":"Nature"},{"key":"74891_CR18","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.4049\/jimmunol.143.4.1265","volume":"143","author":"A Sette","year":"1989","unstructured":"Sette, A., Adorini, L., Colon, S. M., Buus, S. & Grey, H. M. Capacity of intact proteins to bind to MHC class II molecules. J. Immunol. 143, 1265\u20131267 (1989).","journal-title":"J. Immunol."},{"key":"74891_CR19","doi-asserted-by":"crossref","unstructured":"Grippin, A. J. et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature (2025).","DOI":"10.1136\/jitc-2025-SITC2025.0419"},{"key":"74891_CR20","doi-asserted-by":"crossref","unstructured":"Chen, X. et al. An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy. Nat. Cancer 5, 1063\u20131081 (2024).","DOI":"10.1038\/s43018-024-00760-x"},{"key":"74891_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","volume":"72","author":"JC Castle","year":"2012","unstructured":"Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081\u20131091 (2012).","journal-title":"Cancer Res."},{"key":"74891_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1021\/mp200350n","volume":"9","author":"EA Vasievich","year":"2012","unstructured":"Vasievich, E. A., Ramishetti, S., Zhang, Y. & Huang, L. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol. Pharm. 9, 261\u2013268 (2012).","journal-title":"Mol. Pharm."},{"key":"74891_CR23","doi-asserted-by":"publisher","first-page":"e26889","DOI":"10.4161\/onci.26889","volume":"2","author":"F Scrimieri","year":"2013","unstructured":"Scrimieri, F. et al. Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden. Oncoimmunology 2, e26889 (2013).","journal-title":"Oncoimmunology"},{"key":"74891_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0091-6749(97)70248-3","volume":"100","author":"M Willheim","year":"1997","unstructured":"Willheim, M. et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J. Allergy Clin. Immunol. 100, 348\u2013355 (1997).","journal-title":"J. Allergy Clin. Immunol."},{"key":"74891_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00262-019-02448-z","volume":"69","author":"R Zhang","year":"2020","unstructured":"Zhang, R. et al. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. Cancer Immunol. Immunother. 69, 135\u2013145 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"74891_CR26","doi-asserted-by":"crossref","unstructured":"Hay, Z. L. Z. & Slansky, J. E. Granzymes: The Molecular Executors of Immune-Mediated Cytotoxicity. International journal of molecular sciences 23, (2022).","DOI":"10.3390\/ijms23031833"},{"key":"74891_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj, D. et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer cell 35, 885\u2013900.e810 (2019).","journal-title":"Cancer cell"},{"key":"74891_CR28","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1084\/jem.180.6.2401","volume":"180","author":"LM Bradley","year":"1994","unstructured":"Bradley, L. M., Watson, S. R. & Swain, S. L. Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin.  J. Exp. Med. 180, 2401\u20132406 (1994).","journal-title":"J. Exp. Med."},{"key":"74891_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4049\/immunohorizons.1900093","volume":"4","author":"HS Cho","year":"2020","unstructured":"Cho, H. S. et al. CD8(+) T Cells Require ITK-Mediated TCR Signaling for Migration to the Intestine. Immunohorizons 4, 57\u201371 (2020).","journal-title":"Immunohorizons"},{"key":"74891_CR30","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.4049\/jimmunol.178.4.2499","volume":"178","author":"M Matsumoto","year":"2007","unstructured":"Matsumoto, M. et al. CD43 collaborates with P-selectin glycoprotein ligand-1 to mediate E-selectin-dependent T cell migration into inflamed skin. J. Immunol. 178, 2499\u20132506 (2007).","journal-title":"J. Immunol."},{"key":"74891_CR31","doi-asserted-by":"publisher","first-page":"15059","DOI":"10.1073\/pnas.2334901100","volume":"100","author":"M Tone","year":"2003","unstructured":"Tone, M. et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc. Natl. Acad. Sci. USA 100, 15059\u201315064 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74891_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1046\/j.1440-1711.1998.00709.x","volume":"76","author":"MJ Barnden","year":"1998","unstructured":"Barnden, M. J., Allison, J., Heath, W. R. & Carbone, F. R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76, 34\u201340 (1998).","journal-title":"Immunol. Cell Biol."},{"key":"74891_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/0192623315625859","volume":"44","author":"SA Elmore","year":"2016","unstructured":"Elmore, S. A. et al. Recommendations from the INHAND Apoptosis\/Necrosis Working Group. Toxicol. Pathol. 44, 173\u2013188 (2016).","journal-title":"Toxicol. Pathol."},{"key":"74891_CR34","doi-asserted-by":"publisher","first-page":"621254","DOI":"10.3389\/fimmu.2020.621254","volume":"11","author":"EE Peterson","year":"2020","unstructured":"Peterson, E. E. & Barry, K. C. The Natural Killer-Dendritic Cell Immune Axis in Anti-Cancer Immunity and Immunotherapy. Front. Immunol. 11, 621254 (2020).","journal-title":"Front. Immunol."},{"key":"74891_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald, T., Krummel, M. F., Smyth, M. J. & Barry, K. C. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat. Immunol. 21, 835\u2013847 (2020).","journal-title":"Nat. Immunol."},{"key":"74891_CR36","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.  N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"74891_CR37","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.  N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"74891_CR38","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang, Y., Chen, M., Nie, H. & Yuan, Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum. Vaccin Immunother. 15, 1111\u20131122 (2019).","journal-title":"Hum. Vaccin Immunother."},{"key":"74891_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19192-z","volume":"11","author":"T Oba","year":"2020","unstructured":"Oba, T. et al. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat. Commun. 11, 5415 (2020).","journal-title":"Nat. Commun."},{"key":"74891_CR40","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.04.019","volume":"52","author":"T Chu","year":"2020","unstructured":"Chu, T. & Zehn, D. Charting the Roadmap of T Cell Exhaustion. Immunity 52, 724\u2013726 (2020).","journal-title":"Immunity"},{"key":"74891_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang, Y., Li, Y. & Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell death Dis. 6, e1792 (2015).","journal-title":"Cell death Dis."},{"key":"74891_CR42","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/emmm.201302524","volume":"5","author":"JH Yoon","year":"2013","unstructured":"Yoon, J. H. et al. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. EMBO Mol. Med. 5, 1720\u20131739 (2013).","journal-title":"EMBO Mol. Med."},{"key":"74891_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-018-0122-x","volume":"119","author":"T Bald","year":"2018","unstructured":"Bald, T. & Smyth, M. J. TGFbeta shuts the door on T cells. Br. J. cancer 119, 1\u20133 (2018).","journal-title":"Br. J. cancer"},{"key":"74891_CR44","doi-asserted-by":"crossref","unstructured":"Malek, E. et al. Preclinical Studies and a Phase I Trial of the TGF-beta Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide. Blood 132, (2018).","DOI":"10.1182\/blood-2018-99-112449"},{"key":"74891_CR45","doi-asserted-by":"crossref","unstructured":"Kim, T. W. et al. Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer. Journal of Clinical Oncology 39 (2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.3573"},{"key":"74891_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01348-0","volume":"20","author":"JD Beck","year":"2021","unstructured":"Beck, J. D. et al. mRNA therapeutics in cancer immunotherapy. Mol. cancer 20, 69 (2021).","journal-title":"Mol. cancer"},{"key":"74891_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","volume":"22","author":"A Nelde","year":"2021","unstructured":"Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74\u201385 (2021).","journal-title":"Nat. Immunol."},{"key":"74891_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.abd3871","volume":"370","author":"J Mateus","year":"2020","unstructured":"Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Sci. (N. Y., N. Y 370, 89\u201394 (2020).","journal-title":"Sci. (N. Y., N. Y"},{"key":"74891_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100204","volume":"2","author":"A Tarke","year":"2021","unstructured":"Tarke, A. et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep. Med 2, 100204 (2021).","journal-title":"Cell Rep. Med"},{"key":"74891_CR50","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat. Immunol."},{"key":"74891_CR51","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1096\/fj.201800636R","volume":"33","author":"MA Brehm","year":"2019","unstructured":"Brehm, M. A. et al. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J.: Off. Publ. Federation Am. Societies Exp. Biol. 33, 3137\u20133151 (2019).","journal-title":"FASEB J.: Off. Publ. Federation Am. Societies Exp. Biol."},{"key":"74891_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0240-5","volume":"7","author":"J Scholtalbers","year":"2015","unstructured":"Scholtalbers, J. et al. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med 7, 118 (2015).","journal-title":"Genome Med"},{"key":"74891_CR53","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1084\/jem.179.4.1109","volume":"179","author":"F Sallusto","year":"1994","unstructured":"Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.  J. Exp. Med. 179, 1109\u20131118 (1994).","journal-title":"J. Exp. Med."},{"key":"74891_CR54","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1084\/jem.186.1.65","volume":"186","author":"SR Bennett","year":"1997","unstructured":"Bennett, S. R., Carbone, F. R., Karamalis, F., Miller, J. F. & Heath, W. R. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help.  J. Exp. Med. 186, 65\u201370 (1997).","journal-title":"J. Exp. Med."},{"key":"74891_CR55","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","volume":"47","author":"T Ahrends","year":"2017","unstructured":"Ahrends, T. et al. CD4(+) T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity 47, 848\u2013861 e845 (2017).","journal-title":"Immunity"},{"key":"74891_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00273-5","volume":"6","author":"AM Swartz","year":"2021","unstructured":"Swartz, A. M. et al. A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. NPJ Vaccines 6, 12 (2021).","journal-title":"NPJ Vaccines"},{"key":"74891_CR57","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1089\/hum.2012.101","volume":"23","author":"K Oosterhuis","year":"2012","unstructured":"Oosterhuis, K., Aleyd, E., Vrijland, K., Schumacher, T. N. & Haanen, J. B. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Hum. gene Ther. 23, 1301\u20131312 (2012).","journal-title":"Hum. gene Ther."},{"key":"74891_CR58","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3389\/fimmu.2019.02472","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma. Front. Immunol. 10, 2472 (2019).","journal-title":"Front. Immunol."},{"key":"74891_CR59","first-page":"1071","volume":"59","author":"AL Marzo","year":"1999","unstructured":"Marzo, A. L., Lake, R. A., Robinson, B. W. & Scott, B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59, 1071\u20131079 (1999).","journal-title":"Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74891-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:02:12Z","timestamp":1785142932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74891-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74891"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74891-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.P., L.L., S.K., and S. L. are named inventors on a pending patent application relating to PROTEXI and its use for the treatment of cancer. T.P., L.L., J.K.C., and S. Lim are employees of\u00a0Celloram Inc. T.P., J.L., and S.K. serve as board members of Celloram Inc. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6963"}}